Transparency Launches as Linux of Drug Development

Xconomy New York — 

When Tomasz Sablinski was working in pharmaceutical R&D, he was often frustrated by the demand for secrecy in the clinical trials process—a misdirected effort, he says, to keep competitors in the dark about what drug companies were up to. “The price you pay when you hide what you’re doing is you only get feedback from a precious few people,” he says. “There is very little new blood in the ideation process.”

Then Sablinski read an article about the open-source operating system Linux and he had an epiphany. “If said, ‘If computer coders can do open source, so can drug developers,'” he recalls. “You have to add patients to the mix, because they’re really the reason you’re doing drug development.”

So in late January, Sablinski and his company, Transparency Life Sciences, rolled out the beta version of a virtual community of physicians, scientists, and patients whose input is helping the company develop three drugs. The site (, which is being managed by a handful of staff members in New York City and Boston, has only been live for a few weeks. But it has already attracted about 30 patients, who have been actively trading notes about their experiences and making suggestions for clinical trials, Sablinski says.

Sablinski hopes the population of registered users will balloon in the coming weeks, when Transparency begins reaching out to patient advocacy groups in the disease areas it’s working in: multiple sclerosis, peripheral vascular disease, and inflammatory bowel disease. “What we’re trying to do is channel this tremendous Web energy into helping us create experiments that will answer the right questions,” Sablinski says.

Here’s how it works: After people register as users on the site, they pick the drug development program that interests them, and then answer a series of questions about it. For example, users who enter the MS area identify themselves as either patients or researchers. Researchers are asked questions such as “Which patient population should be studied initially?” and then given choices such as “relapsing remitting” and “secondary progressive.” Patients, on the other hand, are asked to recount their experiences, as such: “Please think about medications you have tried for MS. Were you likely to need a lower or higher than usual dose?”

Sablinski says he plans to close out the question-and-answer period on the MS drug in the next two months or so, after which he will choose his principal investigators—possibly from the community of physicians that sign on to the site. From there, he and his team will design a clinical trial and go to the FDA for permission to run it, he says.

Transparency also has a strong social-media component. The site includes a forum where patients can ask questions about diseases and treatments. The forum is moderated by Lisa Abrams, who also answers private letters from patients and is creating a newsletter for patients and families. Abrams, a former drug-development consultant, received a business degree from MIT, where she specialized in studying how technology … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

12 responses to “Transparency Launches as Linux of Drug Development”

  1. Eric says:

    I have been suffering from IBS since 2005. I have tried all the test, including intolerance to guletin. The only medicine that helps some whats is dicyclomine 10mg at least 1 hour before I eat. This only seems to reduce some of the excess pressure. I have to relief myself frequently.

    I would like to help with a development of some treatment for IBS since is really rules my life.

  2. Niels Jensen says:

    Is anyone doing something similar on home apparatus development?

    I monitoring my blood at home by measuring my INR – International Normalized Ratio – a measure of how quickly my blood solidify.

    Currently taking a measurement is a quite complex process involving the
    following steps
    1. Insert a new needle into the needle holder.
    2a. Turn on the measurement device.
    2b. Insert a strip with a microreactor on it into the device.
    2c. Confirm the strip batch number.
    3. Inject the needle into the tip of you.
    4. Squezze out a drop of blood onto the inlet of the microreactor.
    5. Put bandaid on your finger tip to stop bleeding.
    6. Read the result on the measurement device.
    7. Record the result.
    8. Make dose changes as needed based on a chart.
    9. Turn off measurement device.
    10.Dispose off needle and used microreactor.

    I am thinking that since the measurement device has a built-in clock which include date. The the device could be expanded to include things
    like the chart for determining dose from last measurement, and a daily reminder at bedtime – e.g. a flashing red light, which you turn off after taking the daily dose, display of daily dose based on day of the week and last measurement.

    Also the separate needle and measurement device could possibly be combined to a device similar to insulin pens.